BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

808 related articles for article (PubMed ID: 29617669)

  • 1. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
    Ricketts CJ; De Cubas AA; Fan H; Smith CC; Lang M; Reznik E; Bowlby R; Gibb EA; Akbani R; Beroukhim R; Bottaro DP; Choueiri TK; Gibbs RA; Godwin AK; Haake S; Hakimi AA; Henske EP; Hsieh JJ; Ho TH; Kanchi RS; Krishnan B; Kwiatkowski DJ; Liu W; Merino MJ; Mills GB; Myers J; Nickerson ML; Reuter VE; Schmidt LS; Shelley CS; Shen H; Shuch B; Signoretti S; Srinivasan R; Tamboli P; Thomas G; Vincent BG; Vocke CD; Wheeler DA; Yang L; Kim WY; Robertson AG; ; Spellman PT; Rathmell WK; Linehan WM
    Cell Rep; 2018 Apr; 23(1):313-326.e5. PubMed ID: 29617669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.
    Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Parasramka M; Cheville JC; Wu KJ; Frenkel E; Rakheja D; Stefanius K; Brugarolas J; Parker AS
    Urol Oncol; 2015 Jan; 33(1):23.e9-23.e14. PubMed ID: 25465300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
    Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
    Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications.
    Linehan WM; Ricketts CJ
    Nat Rev Urol; 2019 Sep; 16(9):539-552. PubMed ID: 31278395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
    Kapur P; Peña-Llopis S; Christie A; Zhrebker L; Pavía-Jiménez A; Rathmell WK; Xie XJ; Brugarolas J
    Lancet Oncol; 2013 Feb; 14(2):159-167. PubMed ID: 23333114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BAP1 loss defines a new class of renal cell carcinoma.
    Peña-Llopis S; Vega-Rubín-de-Celis S; Liao A; Leng N; Pavía-Jiménez A; Wang S; Yamasaki T; Zhrebker L; Sivanand S; Spence P; Kinch L; Hambuch T; Jain S; Lotan Y; Margulis V; Sagalowsky AI; Summerour PB; Kabbani W; Wong SW; Grishin N; Laurent M; Xie XJ; Haudenschild CD; Ross MT; Bentley DR; Kapur P; Brugarolas J
    Nat Genet; 2012 Jun; 44(7):751-9. PubMed ID: 22683710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
    Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ
    Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expanding role of BAP1 in clear cell renal cell carcinoma.
    Kapur P; Rajaram S; Brugarolas J
    Hum Pathol; 2023 Mar; 133():22-31. PubMed ID: 35932824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commentary on "Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation." Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. Lancet Oncol 2013; 14(2):159-67. [Epub 2013 Jan 16]. doi: 10.1016/S1470-2045(12)70584-3.
    Boorjian S
    Urol Oncol; 2014 Aug; 32(6):934-5. PubMed ID: 25087671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomics and clinical correlates of renal cell carcinoma.
    Mitchell TJ; Rossi SH; Klatte T; Stewart GD
    World J Urol; 2018 Dec; 36(12):1899-1911. PubMed ID: 30099580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
    Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
    BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma.
    Piva F; Giulietti M; Occhipinti G; Santoni M; Massari F; Sotte V; Iacovelli R; Burattini L; Santini D; Montironi R; Cascinu S; Principato G
    Oncotarget; 2015 Oct; 6(31):32161-8. PubMed ID: 26452128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
    Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
    Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.
    Togo Y; Yoshikawa Y; Suzuki T; Nakano Y; Kanematsu A; Zozumi M; Nojima M; Hirota S; Yamamoto S; Hashimoto-Tamaoki T
    Int J Oncol; 2016 Apr; 48(4):1571-80. PubMed ID: 26891804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry.
    Kim SH; Park WS; Park EY; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
    PLoS One; 2017; 12(6):e0179610. PubMed ID: 28654655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linking Binary Gene Relationships to Drivers of Renal Cell Carcinoma Reveals Convergent Function in Alternate Tumor Progression Paths.
    Poehlman WL; Hsieh JJ; Feltus FA
    Sci Rep; 2019 Feb; 9(1):2899. PubMed ID: 30814637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
    Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
    Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploration of Morphological Features of Clear Cell Renal Cell Carcinoma With
    Liu Y; Li Y; Xu H; Zhou L; Yang X; Wang C
    Int J Surg Pathol; 2023 Dec; 31(8):1485-1494. PubMed ID: 36911986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.